Exact Sciences (EXAS) Tops Q4 EPS by 6c, FY Rev. Guidance Beats

Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.44), $0.06 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $143 million versus the consensus estimate of $134.84 million.

GUIDANCE:

Exact Sciences sees FY2019 revenue of $710-730 million, versus the consensus of $704.35 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Worthington Enterprises raises dividend 5%, adds board member
• Qualcomm investor day to detail data center plans Wednesday